BHBenjamin G. Horst

Benjamin G. Horst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin G. Horst has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Michael A. Marletta

    Department of Chemistry, Department of Molecular and Cell Biology, QB3 Institute, University of California, Berkeley, CA USA

    5 shared publications
  • Alan H. Fairlamb

    Affiliation Division of Biological Chemistry & Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom

    2 shared publications
  • Barbara Forte

    Wellcome Centre for Anti-Infectives Research, Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, DD1 5EH Dundee, United Kingdom

    2 shared publications
  • Beatriz Baragaña

    University of Dundee

    2 shared publications
  • Chimed Jansen

    Wellcome Centre for Anti-Infectives Research, Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, DD1 5EH Dundee, United Kingdom

    2 shared publications
  • Chris Walpole

    Structural Genomics Consortium, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada

    2 shared publications

Latest Publications

  • Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity

    by Kai R. Trepka, Wesley A. Kidder, Than S. Kyaw, Taylor Halsey, Christine A. Olson, Edwin F. Ortega, Cecilia Noecker, Vaibhav Upadhyay, Dalila Stanfield, Paige Steiding, et al.

    Dose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Here, we demonstrate the utility of a more comprehensive approach to studying drug toxicity through longitudinal profiling of the human gut microbiome during colorectal cancer (CRC) treatment (NCT04054908) coupled to cell culture and mouse experiments. Substantial shifts in gut microbial community structure during oral fluoropyrimidine treatment across multiple patient cohorts, in mouse small and large intestinal contents, and in patient-derived ex vivo communities were revealed by 16 S rRNA gene sequencing. Metagenomic sequencing revealed marked shifts in pyrimidine-related gene abundance during oral fluoropyrimidine treatment, including enrichment of the preTA operon, which was sufficient for the inactivation of active metabolite 5-fluorouracil (5-FU). preTA + bacteria depleted 5-FU in gut microbiota grown ex vivo and in the mouse distal gut. Germ-free and antibiotic-treated mice experienced increased fluoropyrimidine toxicity, which was rescued by colonization with the mouse gut microbiota, preTA + Escherichia coli , or preTA -high stool from patients with CRC. Last, preTA abundance was negatively associated with fluoropyrimidine toxicity in patients. Together, these data support a causal, clinically relevant interaction between a human gut bacterial operon and the dose-limiting side effects of cancer treatment. Our approach may be generalizable to other drugs, including cancer immunotherapies, and provides valuable insights into host-microbiome interactions in the context of disease.


  • Open Access

    Nitric oxide signaling controls collective contractions in a colonial choanoflagellate

    by Josean Reyes-Rivera, Yang Wu, Benjamin G. H. Guthrie, Michael A. Marletta, Nicole King, Thibaut Brunet

    Although signaling by the gaseous molecule nitric oxide (NO) regulates key physiological processes in animals, including contractility 1-3 , immunity 4,5 , development 6-9 and locomotion 10,11 , the early evolution of animal NO signaling remains unclear. To reconstruct the role of NO in the animal stem lineage, we set out to study NO signaling in choanoflagellates, the closest living relatives of animals 12 . In animals, NO produced by the nitric oxide synthase (NOS) canonically signals through cGMP by activating soluble guanylate cyclases (sGCs) 13,14 . We surveyed the distribution of the NO signaling pathway components across the diversity of choanoflagellates and found three species that express NOS, sGCs, and downstream genes previously shown to be involved in the NO/cGMP pathway. One of these, Choanoeca flexa , forms multicellular sheets that undergo collective contractions controlled by cGMP 15 . We found that treatment with NO induces sustained contractions in C. flexa by signaling through an sGC/cGMP pathway. Biochemical assays show that NO directly binds C. flexa sGC1 and stimulates its cyclase activity. The NO/cGMP pathway acts independently from other inducers of C. flexa contraction, including mechanical stimuli and heat, but sGC activity is required for contractions induced by light-to-dark transitions. The output of NO signaling in C. flexa – contractions resulting in a switch from feeding to swimming – resembles the effect of NO in sponges 1-3 and cnidarians 11,16,17 , where it interrupts feeding and activates contractility. These data provide insights into the biology of the first animals and the evolution of NO signaling.

  • Open Access

    Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy

    by Benjamin G Horst, Adam L Yokom, Daniel J Rosenberg, Kyle L Morris, Michal Hammel, James H Hurley, Michael A Marletta

    Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in mammalian nitric oxide signaling. We determined structures of full-length Manduca sexta sGC in both inactive and active states using cryo-electron microscopy. NO and the sGC-specific stimulator YC-1 induce a 71° rotation of the heme-binding β H-NOX and PAS domains. Repositioning of the β H-NOX domain leads to a straightening of the coiled-coil domains, which, in turn, use the motion to move the catalytic domains into an active conformation. YC-1 binds directly between the β H-NOX domain and the two CC domains. The structural elongation of the particle observed in cryo-EM was corroborated in solution using small angle X-ray scattering (SAXS). These structures delineate the endpoints of the allosteric transition responsible for the major cyclic GMP-dependent physiological effects of NO.


  • Open Access

    Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy

    by Benjamin G. Horst, Adam L. Yokom, Daniel J. Rosenberg, Kyle L. Morris, Michal Hammel, James H. Hurley, Michael A. Marletta

    Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in mammalian nitric oxide signaling. We determined structures of full-length Manduca sexta sGC in both inactive and active states using cryo-electron microscopy. NO and the sGC-specific stimulator YC-1 induce a 71° rotation of the heme-binding β H-NOX and PAS domains. Repositioning of the β H-NOX domain leads to a straightening of the coiled-coil domains, which, in turn, use the motion to move the catalytic domains into an active conformation. YC-1 binds directly between the β H-NOX domain and the two CC domains. The structural elongation of the particle observed in cryo-EM was corroborated in solution using small angle X-ray scattering (SAXS). These structures delineate the endpoints of the allosteric transition responsible for the major cyclic GMP-dependent physiological effects of NO.

  • Characterization of a Carbon Monoxide-Activated Soluble Guanylate Cyclase from Chlamydomonas reinhardtii

    by Benjamin G. Horst, Edna M. Stewart, Aren A. Nazarian, Michael A. Marletta

    Signaling pathways that involve diatomic gases in photosynthetic organisms are not well understood. Exposure to nitric oxide or carbon monoxide is known to elicit certain responses in some photosynthetic organisms. For example, Chlamydomonas reinhardtii grown in low-iron media responds to exogenous carbon monoxide by increasing cell growth and intracellular chlorophyll levels. Here, we characterize Cyg11, a gas-responsive soluble guanylate cyclase from the eukaryotic green alga Chlamydomonas reinhardtii that converts GTP to cGMP. Cyg11 transcription is upregulated when C. reinhardtii is grown in iron-limited media, suggesting its importance in nutrient-limited environments. Cyg11 is purified as a homodimer and is activated by nitric oxide (2.5-fold over basal activity) and carbon monoxide (6.3 fold) The heme binding stoichiometry of Cyg11 was found to be one heme per homodimer, an unexpected result based on the sequence and oligomerization state of the enzyme. Gas binding properties, the kinetics of gas binding, and the ligand-modulated activity of Cyg11 are consistent with CO as the relevant physiological ligand.


  • Top Cited Papers
    Open Access

    Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

    by Beatriz Baragaña, Barbara Forte, Ryan Choi, Stephen Nakazawa Hewitt, Juan A. Bueren-Calabuig, João Pedro Pisco, Caroline Peet, David M. Dranow, David A. Robinson, Chimed Jansen, et al.

    Malaria and cryptosporidiosis, caused by apicomplexan parasites, remain major drivers of global child mortality. New drugs for the treatment of malaria and cryptosporidiosis, in particular, are of high priority; however, there are few chemically validated targets. The natural product cladosporin is active against blood- and liver-stage Plasmodium falciparum and Cryptosporidium parvum in cell-culture studies. Target deconvolution in P. falciparum has shown that cladosporin inhibits lysyl-tRNA synthetase ( Pf KRS1). Here, we report the identification of a series of selective inhibitors of apicomplexan KRSs. Following a biochemical screen, a small-molecule hit was identified and then optimized by using a structure-based approach, supported by structures of both Pf KRS1 and C. parvum KRS ( Cp KRS). In vivo proof of concept was established in an SCID mouse model of malaria, after oral administration (ED 90 = 1.5 mg/kg, once a day for 4 d). Furthermore, we successfully identified an opportunity for pathogen hopping based on the structural homology between Pf KRS1 and Cp KRS. This series of compounds inhibit Cp KRS and C. parvum and Cryptosporidium hominis in culture, and our lead compound shows oral efficacy in two cryptosporidiosis mouse models. X-ray crystallography and molecular dynamics simulations have provided a model to rationalize the selectivity of our compounds for Pf KRS1 and Cp KRS vs. (human) Hs KRS. Our work validates apicomplexan KRSs as promising targets for the development of drugs for malaria and cryptosporidiosis.


  • Open Access

    Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase

    by Stephen Nakazawa Hewitt, David M. Dranow, Benjamin G. Horst, Jan A. Abendroth, Barbara Forte, Irene Hallyburton, Chimed Jansen, Beatriz Baragaña, Ryan Choi, Kasey L. Rivas, et al.

    Plasmodium falciparum (Pf) prolyl-tRNA synthetase (ProRS) is one of the few chemical-genetically validated drug targets for malaria, yet highly selective inhibitors have not been described. In this paper, approximately 40,000 compounds were screened to identify compounds that selectively inhibit PfProRS enzyme activity versus Homo sapiens (Hs) ProRS. X-ray crystallography structures were solved for apo, as well as substrate- and inhibitor-bound forms of PfProRS. We identified two new inhibitors of PfProRS that bind outside the active site. These two allosteric inhibitors showed >100 times specificity for PfProRS compared to HsProRS, demonstrating this class of compounds could overcome the toxicity related to HsProRS inhibition by halofuginone and its analogues. Initial medicinal chemistry was performed on one of the two compounds, guided by the cocrystallography of the compound with PfProRS, and the results can instruct future medicinal chemistry work to optimize these promising new leads for drug development against malaria.


  • Open Access

    cDICE method produces giant lipid vesicles under physiological conditions of charged lipids and ionic solutions

    by Matthew C. Blosser, Benjamin G. Horst, Sarah L. Keller

    The cDICE method produces giant unilamellar vesicles composed of mixtures of phospholipids, even when the lipids are charged and when the surrounding buffer contains high salt. However, cDICE does not incorporate substantial cholesterol into membranes.